receptor interacting serine/threonine kinase 2 | Receptor interacting protein kinase (RIPK) family | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

receptor interacting serine/threonine kinase 2

target has curated data in GtoImmuPdb

Target id: 2190

Nomenclature: receptor interacting serine/threonine kinase 2

Abbreviated Name: RIPK2

Family: Receptor interacting protein kinase (RIPK) family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Contents:

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 540 8q21 RIPK2 receptor interacting serine/threonine kinase 2
Mouse - 539 4 A2 Ripk2 receptor (TNFRSF)-interacting serine-threonine kinase 2
Rat - 539 5 q13 Ripk2 receptor-interacting serine-threonine kinase 2
Previous and Unofficial Names
CARD3 | CARDIAK | CCK | RICK | RIP2
Database Links
BRENDA 2.7.11.1
ChEMBL Target CHEMBL5014 (Hs)
Ensembl Gene ENSG00000104312 (Hs), ENSMUSG00000041135 (Mm), ENSRNOG00000009389 (Rn)
Entrez Gene 8767 (Hs), 192656 (Mm), 362491 (Rn)
Human Protein Atlas ENSG00000104312 (Hs)
KEGG Enzyme 2.7.11.1
KEGG Gene hsa:8767 (Hs), mmu:192656 (Mm), rno:362491 (Rn)
OMIM 603455 (Hs)
RefSeq Nucleotide NM_003821 (Hs), NM_138952 (Mm), NM_001191865 (Rn)
RefSeq Protein NP_003812 (Hs), NP_620402 (Mm), NP_001178794 (Rn)
SynPHARM 83541 (in complex with GSK583)
UniProtKB O43353 (Hs), P58801 (Mm)
Wikipedia RIPK2 (Hs)
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  RIP2 Kinase Catalytic Domain complex with 2(4[(1,3benzothiazol5yl)amino]6(2methylpropane2sulfonyl)quinazolin7yl)oxy)ethyl phosphate
PDB Id:  6RN8
Ligand:  RIPK2 inhibitor 3
Resolution:  2.69Å
Species:  Human
References:  5
Enzyme Reaction
EC Number: 2.7.11.1

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
ZAK inhibitor 6p Hs Inhibition 7.2 pKd 14
⤷ pKd 7.2 (Kd 5.7x10-8 M) [14]
GSK583 Rn Inhibition 8.7 pIC50 6
⤷ pIC50 8.7 (IC50 2x10-9 M) [6]
RIPK2 inhibitor 5 Rn Inhibition 8.7 pIC50 5
⤷ pIC50 8.7 (IC50 2x10-9 M) [5]
Description: Determined in a fluorescence polarisationassay.
RIPK2 inhibitor 8 Hs Inhibition 8.5 pIC50 7
⤷ pIC50 8.5 (IC50 3x10-9 M) [7]
GSK583 Hs Inhibition 8.3 pIC50 6
⤷ pIC50 8.3 (IC50 5x10-9 M) [6]
RIPK2 inhibitor 5 Hs Inhibition 8.3 pIC50 5
⤷ pIC50 8.3 (IC50 5x10-9 M) [5]
Description: Determined in a fluorescence polarisation assay.
OD36 Hs Inhibition 8.3 pIC50 12
⤷ pIC50 8.3 (IC50 5.3x10-9 M) [12]
ponatinib Hs Inhibition 7.8 pIC50 9
⤷ pIC50 7.8 (IC50 1.4x10-8 M) [9]
Description: Inhibition of recombinant RIPK2 in an in vitro ADP-Glo assay (Promega).
Src kinase inhibitor I Hs Inhibition 7.6 pIC50 2
⤷ pIC50 7.6 (IC50 2.6x10-8 M) [2]
PN10 Hs Inhibition 5.8 pIC50 9
⤷ pIC50 5.8 (IC50 1.4x10-6 M) [9]
Description: Inhibition of recombinant human RIPK2 using ADP-Glo assay.
View species-specific inhibitor tables
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 3,13
Key to terms and symbols Click column headers to sort
Target used in screen: RIPK2
Ligand Sp. Type Action Value Parameter
vandetanib Hs Inhibitor Inhibition 8.3 pKd
PD-173955 Hs Inhibitor Inhibition 7.8 pKd
foretinib Hs Inhibitor Inhibition 7.7 pKd
SB203580 Hs Inhibitor Inhibition 7.6 pKd
dasatinib Hs Inhibitor Inhibition 7.5 pKd
PP-242 Hs Inhibitor Inhibition 7.1 pKd
cediranib Hs Inhibitor Inhibition 7.0 pKd
Ki-20227 Hs Inhibitor Inhibition 6.5 pKd
canertinib Hs Inhibitor Inhibition 6.5 pKd
PLX-4720 Hs Inhibitor Inhibition 6.4 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx

Reference: 1,4
Key to terms and symbols Click column headers to sort
Target used in screen: RIPK2/RIPK2
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
K-252a Hs Inhibitor Inhibition 11.4 5.0 3.0
dorsomorphin Hs Inhibitor Inhibition 15.9 14.0 7.0
Cdk1/2 inhibitor III Hs Inhibitor Inhibition 19.7 16.0 29.0
alsterpaullone 2-cyanoethyl Hs Inhibitor Inhibition 21.5 18.0 10.0
vandetanib Hs Inhibitor Inhibition 23.4
dasatinib Hs Inhibitor Inhibition 25.2
Lck inhibitor Hs Inhibitor Inhibition 28.6 21.0 15.0
TWS119 Hs Inhibitor Inhibition 30.5 18.0 11.0
PD 169316 Hs Inhibitor Inhibition 32.8 19.0 25.0
AG 1024 Hs Inhibitor Inhibition 32.8 26.0 16.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Immunopharmacology Comments
RIPK2 is involved in innate immune responses, mediating pro-inflammatory signaling from the bacterial peptidoglycan-sensing NOD1/NOD2 subfamily of innate immune pattern recognition receptors (PRRs) and signalling downstream from the Toll-like receptor (TLR) family of PRRs. Further evidence suggesting an inflammatory role is the targeting of RIPK2 (along with RIPK1/3) by the IAP family E3 ubiquitin ligases (enzymes playing a critical role in innate immunity) [10]. RIPK2 may play a role in driving a range of chronic inflammatory granulomatous diseases (e.g. either loss-of-function of NOD2 or hyperactivation of the NOD2 pathway may contribute to IBD) [8], and since it shares common functionality with RIPK1 and RIPK3, may be involved in necroptosis (a type of programmed cell death, mechanistically and morphologically distinct from apoptosis) [11].
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 8 GO processes
GO:0006954 inflammatory response TAS
GO:0034134 toll-like receptor 2 signaling pathway IDA
GO:0045087 innate immune response IDA
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway TAS
GO:0070431 nucleotide-binding oligomerization domain containing 2 signaling pathway IDA
click arrow to show/hide IEA associations
GO:0034142 toll-like receptor 4 signaling pathway IEA
GO:0045627 positive regulation of T-helper 1 cell differentiation IEA
GO:0070427 nucleotide-binding oligomerization domain containing 1 signaling pathway IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 6 GO processes
GO:0002250 adaptive immune response ISS
GO:0002827 positive regulation of T-helper 1 type immune response IMP
click arrow to show/hide IEA associations
GO:0033091 positive regulation of immature T cell proliferation IEA
GO:0042098 T cell proliferation IEA
GO:0045627 positive regulation of T-helper 1 cell differentiation IEA
GO:0046641 positive regulation of alpha-beta T cell proliferation IEA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 3 GO processes
GO:0002250 adaptive immune response ISS
GO:0002827 positive regulation of T-helper 1 type immune response IMP
click arrow to show/hide IEA associations
GO:0045627 positive regulation of T-helper 1 cell differentiation IEA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 10 GO processes
GO:0002827 positive regulation of T-helper 1 type immune response IMP
GO:0034134 toll-like receptor 2 signaling pathway IDA
GO:0050852 T cell receptor signaling pathway ISS
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway TAS
GO:0070431 nucleotide-binding oligomerization domain containing 2 signaling pathway IDA
click arrow to show/hide IEA associations
GO:0033091 positive regulation of immature T cell proliferation IEA
GO:0034142 toll-like receptor 4 signaling pathway IEA
GO:0045627 positive regulation of T-helper 1 cell differentiation IEA
GO:0046641 positive regulation of alpha-beta T cell proliferation IEA
GO:0070427 nucleotide-binding oligomerization domain containing 1 signaling pathway IEA
Immuno Process:  Cytokine production & signalling
GO Annotations:  Associated to 14 GO processes
GO:0032727 positive regulation of interferon-alpha production NAS
GO:0032728 positive regulation of interferon-beta production NAS
GO:0032735 positive regulation of interleukin-12 production NAS
GO:0050718 positive regulation of interleukin-1 beta secretion IDA
GO:0070498 interleukin-1-mediated signaling pathway TAS
GO:0070555 response to interleukin-1 IMP
click arrow to show/hide IEA associations
GO:0001961 positive regulation of cytokine-mediated signaling pathway IEA
GO:0032722 positive regulation of chemokine production IEA
GO:0032729 positive regulation of interferon-gamma production IEA
GO:0032743 positive regulation of interleukin-2 production IEA
GO:0032755 positive regulation of interleukin-6 production IEA
GO:0032760 positive regulation of tumor necrosis factor production IEA
GO:0070671 response to interleukin-12 IEA
GO:0070673 response to interleukin-18 IEA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 11 GO processes
GO:0031398 positive regulation of protein ubiquitination IMP
GO:0034134 toll-like receptor 2 signaling pathway IDA
GO:0050852 T cell receptor signaling pathway ISS
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway TAS
GO:0070431 nucleotide-binding oligomerization domain containing 2 signaling pathway IDA
click arrow to show/hide IEA associations
GO:0033091 positive regulation of immature T cell proliferation IEA
GO:0034142 toll-like receptor 4 signaling pathway IEA
GO:0042098 T cell proliferation IEA
GO:0045627 positive regulation of T-helper 1 cell differentiation IEA
GO:0046641 positive regulation of alpha-beta T cell proliferation IEA
GO:0070427 nucleotide-binding oligomerization domain containing 1 signaling pathway IEA
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0045627 positive regulation of T-helper 1 cell differentiation IEA
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 4 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0032722 positive regulation of chemokine production IEA
GO:0033091 positive regulation of immature T cell proliferation IEA
GO:0045627 positive regulation of T-helper 1 cell differentiation IEA
GO:0046641 positive regulation of alpha-beta T cell proliferation IEA

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem. J., 408 (3): 297-315. [PMID:17850214]

3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

5. Haile PA, Casillas LN, Votta BJ, Wang GZ, Charnley AK, Dong X, Bury MJ, Romano JJ, Mehlmann JF, King BW et al.. (2019) Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J. Med. Chem., 62 (14): 6482-6494. [PMID:31265286]

6. Haile PA, Votta BJ, Marquis RW, Bury MJ, Mehlmann JF, Singhaus Jr R, Charnley AK, Lakdawala AS, Convery MA, Lipshutz DB et al.. (2016) The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. J. Med. Chem., 59 (10): 4867-80. [PMID:27109867]

7. He X, Da Ros S, Nelson J, Zhu X, Jiang T, Okram B, Jiang S, Michellys PY, Iskandar M, Espinola S et al.. (2017) Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases. ACS Med Chem Lett, 8 (10): 1048-1053. [PMID:29057049]

8. Jun JC, Cominelli F, Abbott DW. (2013) RIP2 activity in inflammatory disease and implications for novel therapeutics. J. Leukoc. Biol., 94 (5): 927-32. [PMID:23794710]

9. Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nogusa S, Shah S, Saleh D, Gough PJ, Bertin J et al.. (2015) Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep, 10 (11): 1850-60. [PMID:25801024]

10. Oberst A. (2016) Death in the fast lane: what's next for necroptosis?. FEBS J., 283 (14): 2616-25. [PMID:26395133]

11. Silke J, Rickard JA, Gerlic M. (2015) The diverse role of RIP kinases in necroptosis and inflammation. Nat. Immunol., 16 (7): 689-97. [PMID:26086143]

12. Tigno-Aranjuez JT, Benderitter P, Rombouts F, Deroose F, Bai X, Mattioli B, Cominelli F, Pizarro TT, Hoflack J, Abbott DW. (2014) In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J. Biol. Chem., 289 (43): 29651-64. [PMID:25213858]

13. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

14. Yang J, Shibu MA, Kong L, Luo J, BadrealamKhan F, Huang Y, Tu ZC, Yun CH, Huang CY, Ding K et al.. (2019) Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. J. Med. Chem., [Epub ahead of print]. [PMID:31244114]

How to cite this page

Receptor interacting protein kinase (RIPK) family: receptor interacting serine/threonine kinase 2. Last modified on 30/07/2019. Accessed on 19/11/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2190.